Clarke S - Search Results

1

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L. Cassidy J, et al. Among authors: clarke s. J Clin Oncol. 2008 Apr 20;26(12):2006-12. doi: 10.1200/JCO.2007.14.9898. J Clin Oncol. 2008. PMID: 18421053 Clinical Trial.

2

Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.

Rosen LS, Abdi E, Davis ID, Gutheil J, Schnell FM, Zalcberg J, Cesano A, Gayko U, Chen MG, Clarke S. Rosen LS, et al. Among authors: clarke s. J Clin Oncol. 2006 Nov 20;24(33):5194-200. doi: 10.1200/JCO.2005.04.1152. Epub 2006 Oct 30. J Clin Oncol. 2006. PMID: 17075109 Clinical Trial.

3

A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.

Van Cutsem E, Verslype C, Beale P, Clarke S, Bugat R, Rakhit A, Fettner SH, Brennscheidt U, Feyereislova A, Delord JP. Van Cutsem E, et al. Among authors: clarke s. Ann Oncol. 2008 Feb;19(2):332-9. doi: 10.1093/annonc/mdm452. Epub 2007 Nov 6. Ann Oncol. 2008. PMID: 17986625 Free article. Clinical Trial.

4

Role of palifermin in fluorouracil-based therapy for metastatic colorectal cancer.

Zalcberg JR, Rosen LS, Abdi E, Davis ID, Gutheil J, Schnell FM, Cesano A, Gayko U, Chen MG, Clarke S. Zalcberg JR, et al. Among authors: clarke s. J Clin Oncol. 2008 Mar 10;26(8):1386-7. doi: 10.1200/JCO.2007.15.4492. J Clin Oncol. 2008. PMID: 18323563 No abstract available.

5

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J. Saltz LB, et al. Among authors: clarke s. J Clin Oncol. 2008 Apr 20;26(12):2013-9. doi: 10.1200/JCO.2007.14.9930. J Clin Oncol. 2008. PMID: 18421054 Clinical Trial.

6

Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.

Sobrero A, Ackland S, Clarke S, Perez-Carrión R, Chiara S, Gapski J, Mainwaring P, Langer B, Young S; AVIRI Trial investigators. Sobrero A, et al. Among authors: clarke s. Oncology. 2009;77(2):113-9. doi: 10.1159/000229787. Epub 2009 Jul 23. Oncology. 2009. PMID: 19628950 Clinical Trial.

7

Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy.

Leighl NB, Shepherd HL, Butow PN, Clarke SJ, McJannett M, Beale PJ, Wilcken NR, Moore MJ, Chen EX, Goldstein D, Horvath L, Knox JJ, Krzyzanowska M, Oza AM, Feld R, Hedley D, Xu W, Tattersall MH. Leighl NB, et al. J Clin Oncol. 2011 May 20;29(15):2077-84. doi: 10.1200/JCO.2010.32.0754. Epub 2011 Apr 11. J Clin Oncol. 2011. PMID: 21483008 Clinical Trial.

8

XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.

Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Rittweger K, Gilberg F, Saltz L. Cassidy J, et al. Among authors: clarke s. Br J Cancer. 2011 Jun 28;105(1):58-64. doi: 10.1038/bjc.2011.201. Epub 2011 Jun 14. Br J Cancer. 2011. PMID: 21673685 Free PMC article. Clinical Trial.

9

Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer.

Mitchell PL, Broad A, Rosenthal MA, Galettis P, Abraham R, Burns I, Clarke S, Milner A, Diiulio J, Links M. Mitchell PL, et al. Among authors: clarke s. Asia Pac J Clin Oncol. 2011 Dec;7(4):376-84. doi: 10.1111/j.1743-7563.2011.01390.x. Epub 2011 May 23. Asia Pac J Clin Oncol. 2011. PMID: 22151988 Clinical Trial.

10

A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer.

Michael M, Pavlakis N, Clingan P, De Boer R, Johnston M, Clarke S. Michael M, et al. Among authors: clarke s. Oncol Rep. 2012 Sep;28(3):763-7. doi: 10.3892/or.2012.1871. Epub 2012 Jun 15. Oncol Rep. 2012. PMID: 22710607 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,884 results

Search Page

Filters